Company Apellis Pharmaceuticals, Inc.
Stocks
APLS
US03753U1060
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.03 USD | -0.07% |
|
-.--% | +63.34% |
Business description: Apellis Pharmaceuticals, Inc.
Number of employees: 736
Sales by Activity: Apellis Pharmaceuticals, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Developing And Commercializing Novel Therapeutics | 66.56M | 75.42M | 397M | 781M | 1B |
Executive Committee: Apellis Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Operating Officer | 56 | 2009-09-24 | |
Timothy Sullivan
DFI | Director of Finance/CFO | 55 | 2017-09-30 |
Leslie Meltzer
CTO | Chief Tech/Sci/R&D Officer | - | 2025-08-24 |
Caroline Baumal
CTO | Chief Tech/Sci/R&D Officer | 59 | 2023-01-02 |
Nur Nicholson
CTO | Chief Tech/Sci/R&D Officer | 57 | 2020-07-31 |
Company details: Apellis Pharmaceuticals, Inc.
Biopharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.07% | -.--% | +111.06% | -52.28% | 5.25B | |
| -0.22% | +2.04% | +16.79% | -8.03% | 67.46B | |
| -0.63% | -7.39% | +37.82% | +199.82% | 51.13B | |
| +0.36% | +40.00% | +40.00% | +40.00% | 43.4B | |
| +0.99% | -1.19% | -49.30% | -53.07% | 40.32B | |
| +4.96% | +0.27% | +55.75% | -24.80% | 30.86B | |
| -1.85% | -18.08% | +99.20% | -47.07% | 26.59B | |
| -2.12% | -1.20% | +66.54% | +84.42% | 22.82B | |
| +0.73% | +2.92% | +9.45% | +176.58% | 19.79B | |
| -2.12% | -3.92% | +61.37% | +130.60% | 16.47B | |
| Average | -0.00% | -3.29% | +44.87% | +44.62% | 32.41B | |
| Weighted average by Cap. | +0.13% | -3.00% | +32.31% | +44.90% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- APLS Stock
- Company Apellis Pharmaceuticals, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
